Novo Nordisk’s new studies presented at ESC Congress 2025 highlight semaglutide’s powerful cardiovascular benefits for people with diabetes and obesity, showing substantial reductions in heart attack, stroke, and cardiovascular death risks with Wegovy, Ozempic, and Rybelsus.
Sanofi’s real-world study shows that infant immunization with BEYFORTUS® offers stronger protection against RSV-related hospitalizations compared to maternal immunization strategies.
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
New active components, such as antibodies, are often evaluated separately in laboratory animals. Researchers at UZH have now created a method that can test up to 25 antibodies in a single mouse. This could not only accelerate the research and development pipeline for new pharmaceuticals, but also significantly reduce the number of experimental animals needed.
Rare yet debilitating disorders, Dravet syndrome, and other developing epileptic encephalopathies induce a variety of symptoms in children, such as seizures, intellectual incapacity, and even [Read More…]
